Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; patient received his first bivalent booster dose on January 4, 2023 lot number 011H22A expiration date 5/23 2023. Patient recived in his left deltoid Patient received vaccine 30 days after beyond use date no other adverse reactions reported; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (patient received his first bivalent booster dose on January 4, 2023 lot number 011H22A expiration date 5/23 2023. Patient recived in his left deltoid Patient received vaccine 30 days after beyond use date no other adverse reactions reported) and NO ADVERSE EVENT (No adverse event) in a 52-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 011H22A) for COVID-19 prophylaxis.     Previously administered products included for COVID-19 prophylaxis: Moderna COVID-19 Vaccine (first Moderna Covid-19 vaccine lot number 031L20A expiration not available. left deltoid muscle) on 11-Feb-2021, Moderna COVID-19 Vaccine (second Moderna Covid-19 vaccine, lot number 003A21A expiration date not available. left arm deltoid muscle. ) on 11-Mar-2021, Moderna COVID-19 Vaccine (first Monovalent Moderna Covid-19 booster dose lot number 066F21A expiration date is not known and on left deltoid muscle) on 01-Nov-2021, Moderna COVID-19 Vaccine (second Moderna Covid-19 vaccine on June 13 and 2022 lot number 001M21A No expiration date is known and on left deltoid muscle) on 13-Jun-2022. Past adverse reactions to the above products included No adverse event with Moderna COVID-19 Vaccine, Moderna COVID-19 Vaccine, Moderna COVID-19 Vaccine and Moderna COVID-19 Vaccine.    On 04-Jan-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 04-Jan-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (patient received his first bivalent booster dose on January 4, 2023 lot number 011H22A expiration date 5/23 2023. Patient recived in his left deltoid Patient received vaccine 30 days after beyond use date no other adverse reactions reported). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (patient received his first bivalent booster dose on January 4, 2023 lot number 011H22A expiration date 5/23 2023. Patient recived in his left deltoid Patient received vaccine 30 days after beyond use date no other adverse reactions reported) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (patient received his first bivalent booster dose on January 4, 2023 lot number 011H22A expiration date 5/23 2023. Patient recived in his left deltoid Patient received vaccine 30 days after beyond use date no other adverse reactions reported).    The patient received his first bivalent booster dose on January 4, 2023 lot number 011H22A expiration date 5/23 2023.  Patient received vaccine 30 days after beyond use date no other adverse reactions reported. Concomitant medications were not reported.  No treatment information was provided